Regional map of medicines
Colombia
95,745people on antiretroviral treatment (2019)
55 %treatment coverage (2013)
Mixedhealth insurance model
Antiretroviral medicines (2013)
| Medicine | Unit price (US$) | Cost per person per year (US$) | Patent in force | Data protection | Monopoly | Possible savings per person per year (US$) |
|---|---|---|---|---|---|---|
| Abacavir 300 mg | 0.08 | 58 | No | No | No | 0 |
| Atazanavir 300 mg | 6.94 | 2,534 | No | Yes | Yes | 2,303 |
| Etravirina 100 mg | 3.25 | 4,738 | No | No | Yes | 4,271 |
| Lopinavir Ritonavir 200mg - 50 mg | 0.55 | 795 | Yes | No | Yes | 426 |
| Raltegravir 400 mg | 10.65 | 7,771 | Yes | No | Yes | 6,019 |
| Emtricitabina Tenofovir 200mg - 300 mg | 0.21 | 77 | No | No | No | -20 |
| Maraviroc 300 mg | — | — | Yes | No | Yes | — |
| Emtricitabina-tenofovir-efavirenz 600 mg - 300 mg - 200 mg | — | — | No | No | No | — |
Epidemiological data
| Year | People on treatment | People without treatment | Treatment coverage |
|---|---|---|---|
| 2013 | 39,397 | 71 | 55 % |
| 2019 | 95,745 | — | — |
Health coverage
- Insurance model
- Mixed (subsidized and contributive)
- Provision of antiretrovirals
- Provided by Entidades Promotoras de Salud (EPS)
- Procurement of antiretrovirals
- Decentralized at each EPS
The data were provided by RedLAM member organizations at the time; each table shows the year.